Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Hold” from Brokerages

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Hold” by the four ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $57.50.

Several analysts recently commented on SNY shares. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th.

Sanofi Stock Up 1.0 %

SNY opened at $57.47 on Friday. The stock has a market capitalization of $145.56 billion, a P/E ratio of 28.88, a price-to-earnings-growth ratio of 1.60 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a one year low of $42.63 and a one year high of $58.97. The business’s 50-day simple moving average is $54.08 and its 200-day simple moving average is $50.35.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 earnings per share. Analysts anticipate that Sanofi will post 4.25 EPS for the current year.

Institutional Trading of Sanofi

Several hedge funds have recently made changes to their positions in the company. Boston Partners boosted its stake in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD grew its stake in shares of Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.